Vera Therapeutics (VERA) Projected to Release Earnings on Thursday

Vera Therapeutics (NASDAQ:VERA) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Vera Therapeutics to post earnings of ($1.62) per share and revenue of $3.42 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.58) by $0.06. During the same quarter last year, the company earned ($1.20) earnings per share. On average, analysts expect Vera Therapeutics to post ($6.45) EPS for the current fiscal year and ($4.55) EPS for the next fiscal year.

Vera Therapeutics Trading Up 1.5%

Shares of Vera Therapeutics stock opened at $30.71 on Wednesday. The firm has a market capitalization of $2.21 billion, a PE ratio of -5.24 and a beta of 1.07. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.18. The firm’s 50 day moving average is $31.90 and its 200 day moving average is $36.91. Vera Therapeutics has a 1 year low of $23.05 and a 1 year high of $56.05.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on VERA shares. JPMorgan Chase & Co. increased their price objective on shares of Vera Therapeutics from $76.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, September 8th. Bank of America boosted their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a report on Wednesday, July 8th. Raymond James Financial reiterated a “strong-buy” rating on shares of Vera Therapeutics in a report on Monday, October 26th. Finally, HC Wainwright dropped their price target on Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $76.86.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total transaction of $684,500.00. Following the sale, the chief executive officer directly owned 235,244 shares in the company, valued at approximately $8,704,028. The trade was a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.